Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double-blind, randomised, non-inferiority trial

Blum J., Winikoff B., Raghavan S., Dabash R., Ramadan M. C., Dilbaz B., ...Daha Fazla

LANCET, cilt.375, sa.9710, ss.217-223, 2010 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 375 Sayı: 9710
  • Basım Tarihi: 2010
  • Doi Numarası: 10.1016/s0140-6736(09)61923-1
  • Dergi Adı: LANCET
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.217-223
  • Yozgat Bozok Üniversitesi Adresli: Hayır

Özet

Background Oxytocin, the gold-standard treatment for post-partum haemorrhage, needs refrigeration, intravenous infusion, and skilled providers for optimum use. Misoprostol, a potential alternative, is increasingly used ad hoc for treatment of post-partum haemorrhage; however, evidence is insufficient to lend support to recommendations for its use. This trial established whether sublingual misoprostol is non-inferior to intravenous oxytocin for treatment of post-partum haemorrhage in women receiving prophylactic oxytocin.